Small Airway Obstruction in Asthma, COPD, ACOS

Mahidol University

Status: Completed

Conditions: Asthma-COPD Overlap Syndrome; Asthma; COPD

Treatments: Other: No any intervention

Study type: Observational

Funder types: Other

Identifiers

NCT03423693

Si527/2015

Details and patient eligibility

About

This study was designed as retrospective chart review to test our hypothesis whether there are the differences in inflammatory and anti-inflammatory mediators between asthmatic and ACOS patients with small airway obstruction, and COPD

Full description

The data including spirometry, lung volume, impulse oscillometry, sputum data, demographic characters within 6 months are collected for later analysis. Sputum supernatants and cytospins are used to determine inflammatory and anti-inflammatory responses in those patients.

Enrollment: 230 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Physician-diagnosed asthma, ACO, and COPD
• Their spirometric, IOS, lung volume, demographic data and sputum samples are available

Exclusion criteria

• Concomitant diseases requiring immunosuppressive therapy
• Being on treatments with NSAIDs, macrolides, statins

Trial design

230 participants in 4 patient groups

Asthma with SAO+

Description:

Asthmatic patients with RV/TLC \> or = 40

Treatment:

Other: No any intervention

Asthma with SAO-

Description:

Asthmatic patients with RV/TLC \< 40

Treatment:

Other: No any intervention

ACO

Description:

Asthmatic patients with smoking \> or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC \< 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 \> or = 200 ml and FEV1% \> or =12% after BD)

Treatment:

Other: No any intervention

COPD

Description:

Patients with history of smoking \> or = 10 pack year with post-BD FEV1/FVC \< 0.7 and negative BD reversibility (absolute increase in FEV1 \< 200 ml and FEV1% \<12% after BD)

Treatment:

Other: No any intervention